These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Carbamazepine-induced pseudolymphoma with CD-30 positive cells. Nathan DL; Belsito DV J Am Acad Dermatol; 1998 May; 38(5 Pt 2):806-9. PubMed ID: 9591791 [TBL] [Abstract][Full Text] [Related]
4. Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. Cogrel O; Beylot-Barry M; Vergier B; Dubus P; Doutre MS; Merlio JP; Beylot C Br J Dermatol; 2001 Jun; 144(6):1235-8. PubMed ID: 11422049 [TBL] [Abstract][Full Text] [Related]
5. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Callot V; Roujeau JC; Bagot M; Wechsler J; Chosidow O; Souteyrand P; Morel P; Dubertret L; Avril MF; Revuz J Arch Dermatol; 1996 Nov; 132(11):1315-21. PubMed ID: 8915309 [TBL] [Abstract][Full Text] [Related]
6. Pseudolymphoma occurring in a tattoo. Kahofer P; El Shabrawi-Caelen L; Horn M; Kern T; Smolle J Eur J Dermatol; 2003; 13(2):209-12. PubMed ID: 12695144 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma. Dar NR; Shaheen ; Mustafvi SA; Raza N J Coll Physicians Surg Pak; 2005 Aug; 15(8):496-7. PubMed ID: 16202363 [TBL] [Abstract][Full Text] [Related]
8. [Pseudolymphoma syndrome following use of carbamazepine]. Rondas AA; Froeling PG Ned Tijdschr Geneeskd; 1993 Jun; 137(25):1258-9. PubMed ID: 8327012 [TBL] [Abstract][Full Text] [Related]
9. Pseudolymphoma syndrome due to carbamazepine. Saeki H; Etoh T; Toda K; Mihm MC J Dermatol; 1999 May; 26(5):329-31. PubMed ID: 10380435 [TBL] [Abstract][Full Text] [Related]
10. Drug-associated lymphoma and pseudolymphoma: recognition and management. Albrecht J; Fine LA; Piette W Dermatol Clin; 2007 Apr; 25(2):233-44, vii. PubMed ID: 17430760 [TBL] [Abstract][Full Text] [Related]
11. Cutaneous pseudolymphoma induced by Cimicifuga racemosa. Meyer S; Vogt T; Obermann EC; Landthaler M; Karrer S Dermatology; 2007; 214(1):94-6. PubMed ID: 17191056 [TBL] [Abstract][Full Text] [Related]
12. Pseudoclonality in cutaneous pseudolymphomas: a pitfall in interpretation of rearrangement studies. Böer A; Tirumalae R; Bresch M; Falk TM Br J Dermatol; 2008 Aug; 159(2):394-402. PubMed ID: 18547309 [TBL] [Abstract][Full Text] [Related]
13. Cutaneus pseudolymphoma: a case report. Dragonetti E; Cianchini G; Mastrangelo L; Mellone P; Baldi A In Vivo; 2004; 18(5):549-51. PubMed ID: 15523891 [TBL] [Abstract][Full Text] [Related]
14. [Febrile toxiderma in children]. Larrègue M; Vabres P; Auriol F Rev Prat; 1997 Sep; 47(13):1452-7. PubMed ID: 9339026 [TBL] [Abstract][Full Text] [Related]
15. [Misleading or rare cutaneous drug reactions]. Souteyrand P; d'Incan M; Parent S Rev Prat; 2000 Jun; 50(12):1329-33. PubMed ID: 10972075 [TBL] [Abstract][Full Text] [Related]
16. Cutaneous B-cell pseudolymphoma at the site of vaccination. Cerroni L; Borroni RG; Massone C; Chott A; Kerl H Am J Dermatopathol; 2007 Dec; 29(6):538-42. PubMed ID: 18032948 [TBL] [Abstract][Full Text] [Related]
17. [Pseudolymphoma of the skin: ambiguous terminology: a survey among dermatologists and pathologists]. Levy E; Godet J; Cribier B; Lipsker D Ann Dermatol Venereol; 2013 Feb; 140(2):105-11. PubMed ID: 23395491 [TBL] [Abstract][Full Text] [Related]